XNCR - Stock Analysis & Overview

About Xencor, Inc.

Biotechnology

Healthcare

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma...

Xencor, Inc. Key Metrics

Market Cap: $1B
52 Weeks Low: $15.31
52 Weeks High: $26.84
P/B: 2.28x
P/E: -7.25x
P/S: 10.91x

Upcoming Events

XNCR Analyst Forecasts

‌

XNCR Financials

XNCR Income Statement Key Metrics

Revenue(TTM)133.62 M
Gross Profit(TTM)121.19 M
EBITDA(TTM)-162.78 M
Net Income(TTM)-177.36 M
EPS Diluted(TTM)-2.89

Decode XNCR's Latest Earnings Call with Ease

Tap 'Generate' for a crystal-clear,
AI-crafted summary and stay ahead in the investment game!

XNCR earnings and revenue history

Gross Profit Margin vs Peers

Profit margin ratio of XNCR (0.932) is higher than the average of its peers (-0.246).

Net Profit Margin vs Peers

Net profit margin ratio of XNCR (-0.749) is higher than the average of its peers (-89.842).

XNCR Return on Equity

See how efficiently XNCR generates profit for it's shareholders.

-18.85%

100

Poor

Average

Strong

Return on Equity vs Peers

Return on Equity ratio of XNCR (-0.189) is higher than the average of its peers (-0.494).

Return on Equity Growth

XNCR's Return on Equity has shown poor growth over the past 10 years, increasing by only -3.77%.

XNCR Revenue Growth

See how XNCR has grown it's revenue over the past 10 years.

‌

Revenue Growth

XNCR's revenue has grown significantly over the past 10 years, increasing by over 33.28%.

Xencor, Inc.

Page title

Section title